-
1 Comment
Kymera Therapeutics, Inc is currently in a long term downtrend where the price is trading 3.1% below its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.1.
Based on the above factors, Kymera Therapeutics, Inc gets an overall score of 1/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US5015751044 |
Sector | Healthcare |
Industry | Biotechnology |
Market Cap | 3B |
---|---|
PE Ratio | None |
Target Price | 62.3158 |
Beta | 2.07 |
Dividend Yield | None |
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for KYMR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025